U.S. markets closed
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow 30

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Russell 2000

    2,245.94
    -85.52 (-3.67%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • Gold

    1,788.10
    +1.20 (+0.07%)
     
  • Silver

    23.14
    -0.40 (-1.70%)
     
  • EUR/USD

    1.1322
    +0.0110 (+0.99%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • GBP/USD

    1.3342
    +0.0022 (+0.16%)
     
  • USD/JPY

    113.2600
    -2.0790 (-1.80%)
     
  • BTC-USD

    54,281.57
    -135.04 (-0.25%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,751.62
    -747.66 (-2.53%)
     

Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials.

  • The studies were conducted independently by the Hadassah Medical Center, Israel.

  • IMM124E is used to manufacture Immuron's flagship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn.

  • The paper examines the ability of IMM-124E to promote antiviral interferon-γ (IFNγ) T cell responses in a mouse model and five healthy human volunteers.

  • The research study aimed to determine the ability of IMM-124E to promote antiviral interferon γ (IFNγ) T cell responses.

  • In the preclinical study, data showed that IMM124E enhanced antiviral immunity across the viral strains tested. A similar response was observed in the human study.

  • Healthy volunteers received IMM-124E orally, at a daily dose of 600 mg for four consecutive days and 1200 mg for an additional day.

  • The preliminary clinical data suggested a similar effect in humans in augmenting antiviral responses against COVID-19 and Hepatitis B.

  • Immuron previously reported research investigations on IMM-124E demonstrated neutralizing activity against COVID-19 infection.

  • Price Action: IMRN stock is up 11.90% at $3.94 during the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.